These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 112818)

  • 1. Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery.
    Barbarino A; de Marinis L; Menini E; Anile C; Maira G
    Acta Endocrinol (Copenh); 1979 Jul; 91(3):397-409. PubMed ID: 112818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery.
    Barbarino A; De Marinis L; Anile C; Menini E; Merlini G; Maira G
    Metabolism; 1982 Nov; 31(11):1100-4. PubMed ID: 6813636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prolactin response to thyrotropin-releasing hormone and metoclopramide in patients with prolactin-secreting tumors before and after transsphenoidal surgery.
    Barbarino A; De Marinis L; Maira G; Menini E; Anile C
    J Clin Endocrinol Metab; 1978 Nov; 47(5):1148-51. PubMed ID: 122421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal regulation of prolactin secretion after successful surgery for prolactin-secreting pituitary tumours.
    Schlechte JA; Sherman BM
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):165-74. PubMed ID: 6796301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.
    Scanlon MF; Peters JR; Salvador J; Richards SH; John R; Howell S; Williams ED; Thomas JP; Hall R
    Clin Endocrinol (Oxf); 1986 Apr; 24(4):435-46. PubMed ID: 3091297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of metoclopramide, TRH and L-dopa on prolactin secretion in pituitary adenoma and in "functional" galactorrhoea syndrome.
    Jeske W
    Acta Endocrinol (Copenh); 1979 Jul; 91(3):385-96. PubMed ID: 112817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients.
    De Marinis L; Mancini A; Minnielli S; Masala R; Anile C; Maira G; Barbarino A
    Metabolism; 1985 Oct; 34(10):917-22. PubMed ID: 4046835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin dynamics in patients with non-secretin tumours of the hypothalamic-pituitary region.
    Barbarino A; De Marinis L; Mancini A; Menini E; D'Amico C; Passeri M; Sambo P; Anile C; Maira G
    Acta Endocrinol (Copenh); 1985 Sep; 110(1):10-6. PubMed ID: 3929517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interrelationships between prolactin and thyrotrophin secretion following dopaminergic blockage in patients with mild hyperprolactinaemia without any demonstrable pituitary tumour.
    Spitz IM; Haas M; Trestian S; Zylber-Haran E; Shilo S
    Clin Endocrinol (Oxf); 1983 Sep; 19(3):285-94. PubMed ID: 6414745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic value of pharmacodynamic tests in the hyperprolactinaemic syndrome.
    Ayalon D; Persitz E; Ravid R; Jedwab G; Avidan S; Cordova T; Harell A
    Clin Endocrinol (Oxf); 1979; 11(2):201-15. PubMed ID: 114343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M; Yamaji T
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic evaluation of prolactin secretion by successive TRH and metoclopramide stimulations.
    Kauppila A; Heikkinen J; Viinikka L
    Acta Endocrinol (Copenh); 1986 Jan; 111(1):10-6. PubMed ID: 3080846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of thyrotropin-releasing hormone in distinguishing prolactin-secreting pituitary adenoma.
    Marrs RP; Bertolli SJ; Kletzky OA
    Am J Obstet Gynecol; 1980 Nov; 138(6):620-5. PubMed ID: 6776812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.
    Shimatsu A; Murabe H; Nakamura Y; Mizuta H; Ihara C; Nakao K
    Endocr J; 1999 Feb; 46(1):159-65. PubMed ID: 10426581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal response of luteinizing hormone beta subunit to thyrotrophin-releasing hormone in patients with non-functioning pituitary adenoma.
    Gil-del-Alamo P; Pettersson KS; Saccomanno K; Spada A; Faglia G; Beck-Peccoz P
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):661-6. PubMed ID: 7828356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.
    Webster J; Page MD; Bevan JS; Richards SH; Douglas-Jones AG; Scanlon MF
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):35-44. PubMed ID: 1559298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin dynamics and tumour size in the prediction of surgical outcome for prolactinoma.
    Gordon D; Richards A; Bulloch R; Cohen HN; Semple CG; Beastall GH; Thomson JA; Teasdale G
    Q J Med; 1985 Feb; 54(214):141-51. PubMed ID: 3920723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ritanserin, specific 5HT-2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions.
    Falaschi P; Rosa M; Rocco A; D'Urso R; Proietti A; Melis GB
    Clin Endocrinol (Oxf); 1991 Jun; 34(6):449-53. PubMed ID: 1909607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia.
    Ho KY; Smythe GA; Compton PJ; Lazarus L
    Aust N Z J Med; 1985 Apr; 15(2):213-9. PubMed ID: 3927887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum prolactin in patients with "functionless" chromophobe adenomas before and after therapy.
    Samaan NA; Leavens ME; Jesse JH
    Acta Endocrinol (Copenh); 1977 Mar; 84(3):449-60. PubMed ID: 402758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.